Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 4/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
| ▸ | HTR1D | P28221 | 2/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | HTR1E | P28566 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | HTR1F | P30939 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | RB1 | P06400 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7031093 | 1.00 | HTR1B (0.61) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| SCHEMBL980209 | 1.00 | HTR1B (0.61) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Bromide SCHEMBL7027435 | 0.99 | HTR1B (0.60) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Hydrochloric Acid SCHEMBL3466984 | 0.99 | HTR1B (0.60) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| SCHEMBL7026151 | 0.94 | HTR1B (0.59) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Oxalic Acid SCHEMBL7540895 | 0.94 | HTR1B (0.62) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Succinic Acid SCHEMBL7700352 | 0.92 | HTR1B (0.68) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Succinic Acid SCHEMBL7024837 | 0.92 | HTR1B (0.68) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Succinic Acid SCHEMBL16318529 | 0.91 | HTR1B (0.69) | HTR1BHTR1AHTR1DDRD2DRD4 | |
| Succinic Acid SCHEMBL7025602 | 0.91 | HTR1B (0.69) | HTR1BHTR1AHTR1DDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070051-B1 | PROCESS FOR THE PRODUCTION OF R-(+)-6- CARBOXAMIDO- 3-N- METHYLAMINO- 1,2,3,4- TETRAHYDROCARBAZOLE | VERNALIS DEV LTD (GB) | 2015-06-03 | — | — | EP | claimed |
| JP-4756740-B2 | — | — | 2011-08-24 | — | — | JP | claimed |
| WO-2010073253-A1 | METHOD FOR PREPARING AN OPTICALLY ACTIVE FROVATRIPTAN | NATCO PHARMA LIMITED (IN) | 2010-07-01 | — | — | WO | claimed |
| CN-1200931-C | Preparation method of R- (+) -6-formamido-3-N-methylamino-1, 2,3, 4-tetrahydrocarbazole | FINARIS CO LTD (GB) | 2005-05-11 | — | — | CN | claimed |
| US-6359146-B1 | RESOLUTION OF ENANTIOMORPH MIXTURE | VERNALIS LIMITED (GB) | 2002-03-19 | — | — | US | claimed |
| EP-1070051-A1 | PROCESS FOR THE PRODUCTION OF R-(+)-6- CARBOXAMIDO- 3-N- METHYLAMINO- 1,2,3,4- TETRAHYDROCARBAZOLE | Vernalis Limited (GB) | 2001-01-24 | — | — | EP | claimed |
| WO-1999054302-A1 | PROCESS FOR THE PRODUCTION OF R-(+)-6- CARBOXAMIDO- 3-N- METHYLAMINO- 1,2,3,4- TETRAHYDROCARBAZOLE | VERNALIS LIMITED (GB) | 1999-10-28 | — | — | WO | claimed |
| EP-4335504-A2 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma ApS (DK) | 2024-03-13 | — | — | EP | disclosed |
| EP-3897641-B1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA AS (DK) | 2023-11-15 | — | — | EP | disclosed |
| EP-3897641-A1 | TREATMENT OF MOVEMENT DISORDERS | Contera Pharma A/S (DK) | 2021-10-27 | — | — | EP | disclosed |
| CN-107635555-B | Use of buspirone metabolites | 康特拉医药公司 | 2021-02-26 | — | — | CN | disclosed |
| US-10736878-B2 | Treatment of organophosphate exposure with triptans | PFADENHAUER TINA (US) | 2020-08-11 | — | — | US | disclosed |
| WO-2020127954-A1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA APS (DK) | 2020-06-25 | — | — | WO | disclosed |
| US-5917054-A | ALKYLATING ENANTIOMER OF 3-AMINO-6-CARBOXAMIDO-1,2,3,4-TETRAHYDROCARBAZOLE OR A SALT | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-06-29 | — | — | US | disclosed |
| US-5650426-A | Enantiomers of carbazole derivatives as 5-HT.sub. 1-like agonists | SMITHKLINE BEECHAM PLC (GB) | 1997-07-22 | — | — | US | disclosed |
| US-5618947-A | SEPARATING THE RACEMIC MIXTURE BY CHROMATOGRAPHY | SMITHKLINE BEECHAM, P.L.C. (GB) | 1997-04-08 | — | — | US | disclosed |
| US-5618948-A | TREATMENT OF 6-CARBOXAMIDO-3-METHYLAMINO-1,2,3,4-TETRAHYDROCARBAZOLE WITH 2-PYRROLIDONE-5-CARBOXYLIC ACID, CRYSTALLIZATION | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-04-08 | — | — | US | disclosed |
| US-5616603-A | TREATING MIGRAINES | SMITHKLINE BEECHAM PLC (GB) | 1997-04-01 | — | — | US | disclosed |
| EP-0674621-A1 | ENANTIOMERS OF CARBAZOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014772-A1 | ENANTIOMERS OF CARBAZOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10736878-B2 | Treatment of organophosphate exposure with triptans | DDT, THOP1, TPP1 | HTR1B 1868/4885HTR1A 957/4885HTR1D 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.